npj Breast Cancer (Mar 2017)

Dramatic response of metaplastic breast cancer to chemo-immunotherapy

  • Sylvia Adams

DOI
https://doi.org/10.1038/s41523-017-0011-0
Journal volume & issue
Vol. 3, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.